Neutral
AbbVie (ABBV) recently received European Commission approval to expand the label for its drug Venclyxto, allowing its use with acalabrutinib and ibrut...
Neutral
AbbVie Inc. (NYSE: ABBV) has received European Commission authorization to expand the label for its cancer drug VENCLYXTO. This approval allows for ne...
Bullish
The European Commission has authorized an expanded label for AbbVie's VENCLYXTO (venetoclax) in previously untreated adult chronic lymphocytic leukemi...
Bullish
Ironwood Pharmaceuticals and AbbVie have received FDA approval for a label expansion of their bowel disorder therapy, Linzess. The drug is now indicat...
Bullish
In CNBC's "Final Trades," analysts discussed their picks: AbbVie (ABBV), Deckers Outdoor (DECK), and Goldman Sachs (GS). AbbVie recently received a po...
Bullish
Piper Sandler has increased its price target for AbbVie Inc. (ABBV) to $298 from $294, maintaining an Overweight rating, citing the company's robust i...
Neutral
North Star Asset Management Inc. cut its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 2.5% in the fourth quarter, according to the c...
Neutral
AbbVie Inc. (NYSE:ABBV) is highlighted as one of the best low-risk stocks for 2026, primarily due to recent clinical trial data for its IBD therapies,...
Bullish
The EU drug regulator's expert panel has recommended eight new medicines for approval this week, benefiting companies like Merck, AstraZeneca, and Abb...
Bullish
AbbVie (ABBV) has received a positive opinion from the European Medicines Agency for its oral antiviral treatment, Maviret, targeting acute hepatitis ...
Bullish
AbbVie announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending th...
Neutral
This article examines three high-yield healthcare stocks—Pfizer, AbbVie, and Medtronic—detailing their unique dividend profiles and business models fo...
Neutral
AbbVie's latest quarterly results show a continued transition away from its former blockbuster drug Humira, with significant growth from immunology dr...
Bullish
Evercore ISI has slightly lowered its price target for AbbVie (ABBV) from $236 to $235, while maintaining an 'Outperform' rating. This adjustment foll...
Bullish
TD Private Client Wealth LLC reduced its stake in AbbVie Inc. by 12.6% in the fourth quarter, selling 9,822 shares to hold 68,073 shares valued at app...
Bullish
The North Dakota State Investment Board recently acquired 60,762 shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, valuing their new positi...
Bullish
AbbVie Inc. is drawing investor attention in May 2026 due to new clinical data for its immunology drug Skyrizi in inflammatory arthritis and its consi...
Bullish
AbbVie Inc. has reported stronger-than-expected first-quarter 2026 results, with net revenues reaching $15.0 billion and adjusted earnings per share h...
Neutral
Pure Financial Advisors LLC increased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 74.6% during the fourth quarter, according to its most rec...
Bullish
AbbVie Inc. reported strong double-digit revenue growth in Q1 2026, driven primarily by its immunology drugs Skyrizi and Rinvoq, and its aesthetics po...